公司服务主要涵盖生物医药早期成药性评价、非临床研究以及临床检测及转化研究三大板块，其中非临床研究板块具体包括非临床安全性评价、非临床药代动力学研究、非临床药效学研究。经过多年的发展与积累，发行人在国内非临床安全性评价细分领域市场占有率排名前三，处于行业领先地位。Innothink (688710.SH) released its IPO prospectus for the first time and was listed on Star Market. This time the company...
According to Zhong Tong Finance, Innothink (688710.SH) released its IPO prospectus for the first time and was listed on Star Market. The company issued 35.2449 million shares of stock, which represents 25% of the total share capital of the company after this issuance. The initial inquiry date is August 20, 2024, and the subscription date is August 23, 2024.
It is reported that the issuer is a comprehensive research and development service (CRO) company, focusing on providing non-clinical research services for bio-pharmaceuticals. It is one of the first companies in the domestic industry to have both NMPA GLP certification, OECD GLP certification, and pass the US FDA GLP inspection. It meets international standards and has internationally competitive service capabilities in the industry, providing comprehensive new drug research services that comply with domestic and international application standards for pharmaceutical companies and research institutions worldwide.
The company's services mainly cover three major areas: early evaluation of bio-pharmaceuticals, non-clinical research, and clinical testing and transformation research. Among them, the non-clinical research sector includes non-clinical safety evaluation, non-clinical pharmacokinetic research, and non-clinical pharmacological research. After years of development and accumulation, the issuer ranks among the top three in the domestic non-clinical safety evaluation sub-field market share and is in a leading position in the industry.
The company achieved a net profit attributable to shareholders of the issuer of RMB 86.7274 million, RMB 0.135 billion, and RMB 0.194 billion in 2021, 2022 and 2023, respectively.
After deducting the issuance expenses, the total amount of funds raised for investment projects in this financing round will not exceed RMB 1.602 billion. The specific investment projects are as follows: 1. Innothink headquarters and innovation conversion center, plan to invest RMB 1.045 billion from the raised funds; 2. Comprehensive evaluation platform for high-quality non-clinical innovative drugs expansion project, plan to invest RMB 0.357 billion from the raised funds; 3. Supplementary working capital, plan to invest RMB 0.2 billion from the raised funds.
